"the global annual market for OSA detection and treatment using CPAP and other breathing aides is approximately US$10 billion per annum and growing2. OSA is highly prevalent, affecting approximately 30 million adults in the United States alone."
Ihl's drug is the only solution for the OSA's treatment. The CPAP machines are there to detect problems so the drug is capable to win the market shares.
To prove efficacy for phase 2 study, the company is allowed to use the drug on patients to market its product. The stronger the customer base the faster approval, no questions ask. No trials are needed, just do it and prove it that you can earn incomes my friend, IHL.
IHL Price at posting:
10.3¢ Sentiment: Buy Disclosure: Held
